Wall Street Zen upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Free Report) from a hold rating to a buy rating in a research report report published on Saturday morning.
Separately, Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft to a "hold" rating in a report on Monday, April 28th.
Check Out Our Latest Research Report on BAYRY
Bayer Aktiengesellschaft Price Performance
Shares of OTCMKTS BAYRY traded down $0.12 during midday trading on Friday, reaching $7.12. 343,859 shares of the company were exchanged, compared to its average volume of 821,264. The stock's 50-day moving average price is $6.37 and its 200-day moving average price is $5.82. The stock has a market cap of $27.98 billion, a P/E ratio of -27.38 and a beta of 0.84. Bayer Aktiengesellschaft has a one year low of $4.79 and a one year high of $8.58. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The company had revenue of $15.27 billion for the quarter, compared to analysts' expectations of $13.39 billion. On average, sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.
Bayer Aktiengesellschaft Increases Dividend
The business also recently declared a dividend, which was paid on Monday, May 12th. Investors of record on Wednesday, April 30th were issued a $0.0224 dividend. This represents a dividend yield of 0.38%. The ex-dividend date was Tuesday, April 29th. This is a boost from Bayer Aktiengesellschaft's previous dividend of $0.02. Bayer Aktiengesellschaft's payout ratio is -2.17%.
About Bayer Aktiengesellschaft
(
Get Free Report)
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
See Also
Before you consider Bayer Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.
While Bayer Aktiengesellschaft currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
